IMEL Biotherapeutics is developing a cell-based therapy that represents a new paradigm for the treatment of patients with mitochondrial disorders. Using its proprietary Mitochondrial Replaced Cells technology, IMEL will enable the treatment of multiple patients with mitochondrial genetic or age-related disorders.
Download IMEL’s company profile
Field:BioPharma
Status:Private
Location: United States, Massachusetts, Waltham
Employees: 1-10